Back to Search
Start Over
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.
- Source :
-
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2022 Feb; Vol. 58, pp. 103424. Date of Electronic Publication: 2021 Nov 22. - Publication Year :
- 2022
-
Abstract
- Post-vaccination disease relapses have been reported in patients with MOGAD and AQP4-IgG+NMOSD. In this retrospective multicenter Italian study we assessed the frequency of relapses after SARS-CoV-2 vaccination. We included 56 cases: MOGAD, 30; AQP4-IgG+NMOSD, 26. Vaccines received were BNT162b2-Pfizer-BioNTech in 42 patients and mRNA-1273-Moderna in 14 patients. Six patients had a history of SARS-CoV-2 infection; two of them experienced a post-infection disease relapse (MOGAD). The frequency of relapses within one month of SARS-CoV-2 vaccination was 4% (1/26) in the AQP4-IgG+NMOSD group and 0% in the MOGAD group. In these patients the potential benefits of vaccination overcome the risk of relapses.<br /> (Copyright © 2021 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2211-0356
- Volume :
- 58
- Database :
- MEDLINE
- Journal :
- Multiple sclerosis and related disorders
- Publication Type :
- Report
- Accession number :
- 35216793
- Full Text :
- https://doi.org/10.1016/j.msard.2021.103424